Emphasizing enhanced time-of-flight performance and an energy-efficient design, the Biograph Trinion PET/CT system can reportedly be utilized for a variety of imaging needs, ranging from theranostic applications to neurology imaging.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Biograph Trinion positron emission tomography/computed tomography (PET/CT) system, which made its debut at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
Combining an air-cooled digital detector with bolstered time-of-flight performance, the Biograph Trinion system enables a variety of post-processing applications, including oncologic, cardiovascular, and neurologic imaging as well as theranostics, according to Siemens Healthineers, the manufacturer of the Biograph Trinion.
Combining an air-cooled digital detector with bolstered time-of-flight performance, the Biograph Trinion system enables a variety of post-processing applications, according to Siemens Healthineers, the manufacturer of the newly FDA-cleared PET/CT system. (Image courtesy of Siemens Healthineers.)
The company emphasized that the device’s computer technology is located in the system gantry, allowing a more compact design that can be accommodated in an existing traditional PET/CT room. Siemens Healthineers added that the system’s smart power-save mode for powering down at night, can lead to a 46 percent reduction in energy costs.
“With the Biograph Trinion, Siemens Healthineers is proud to offer customers a high-performance PET/CT scanner that delivers the precision and speed needed for clinical demands,” said James Williams, PhD, head of Molecular Imaging at Siemens Healthineers. “This new system is designed to be user- and patient focused as well as a sustainable investment in terms of reduced installation and operational costs and easy, on-site scalability.”
New Study Shows Non-Radiologists Interpreting 28 Percent of Imaging for Medicare Patients
June 28th 2024While radiologists interpreted approximately 99 percent of all non-cardiac CT, MRI and nuclear medicine studies in hospital and emergency department settings for Medicare beneficiaries, new research shows significantly less radiologist review of cardiac imaging and office-based imaging.
Study Examines Prognostic Value of 68Ga-PSMA-11 PET/CT for Patients at High Risk of PCa
June 21st 2024Initial detection of metastatic prostate cancer via 68Ga-PSMA-11 PET/CT was significantly associated with PSA values > 20 ng/ml, ISUP grade > 3 and MRI T-stage > 3, according to research presented recently at the SNMMI conference.
Study Shows PET/CT is Superior to SPECT/CT in Managing Patients with Primary Hyperparathyroidism
June 21st 2024F18-choline PET/CT imaging guidance for minimally invasive parathyroidectomy (MIP) procedures led to a 29 percent higher percentage of normocalcemia at one month post-op in comparison to imaging guidance with Tc99m-sestaMIBI (MIBI) SPECT/CT, according to new research.
Can Deep Learning Automate Amyloid Positivity Assessment on Brain PET Imaging?
June 14th 2024In validation testing with 205 18F florbetapir PET scans from 95 patients with Alzheimer’s disease, a deep learning model demonstrated a 93.2 percent accuracy rate and a 97 percent AUC for detecting amyloid-β positivity.